OKYO Pharma received positive feedback from the FDA supporting its plan to advance urcosimod into a global Phase 3 trial for neuropathic corneal pain. The FDA agreed with the proposed single-dose study design and indicated a potential single-trial registration pathway, pending successful results. The NEPTUNE trial will enroll about 111 patients in the US and Europe, randomizing them to urcosimod or placebo. OKYO also plans to seek Breakthrough Therapy Designation to speed development and regulatory review, aiming to bring a first-in-class, non-opioid treatment to patients with no current FDA-approved options.
Mint Innovation appointed Matt Bedingfield as Global CEO and spun off its lithium-ion battery recovery business into a new company called Linca, led by co-founder Dr. Ollie Crush. This move allows Mint to concentrate on recovering metals from printed...
Sandler, part of Trilliad, introduced the Sales Performance Ecosystem, the first platform to evaluate sales skills during actual buyer conversations using AI-powered coaching. This system links training directly to revenue by measuring real behavior ...
Pacira BioSciences awarded inducement grants to 10 new employees, including stock options for 9,200 shares and restricted stock units for 18,200 shares, as part of its Amended 2014 Inducement Plan. These awards, approved by the company's compensation...
Bitdeer Technologies introduced the Sealminer A4 Ultra Hydro, a Bitcoin mining machine capable of over 1 petahash per second (PH/s), meaning it can perform more than one quadrillion calculations per second. This single unit replaces what used to requ...
Bull Bitcoin, a non-custodial Bitcoin exchange, has filed a legal petition in France to annul Decree No. 2025-1276, which implements the EU's DAC8 directive requiring crypto service providers to report extensive user data to tax authorities. The comp...
